R&D Views & Analysis | pharmaphorum

Views & Analysis

Patients

Houses of Parliament - a Labour government

Labour, the NHS, and life sciences: Partnerships and people

The United Kingdom this morning woke to landslide poll results: Labour is in on just 34% of the vote following the worst Conservative defeat in the party’s history.

R&D

Innovation in generics: Increased efficiency through peptide...

With the healthcare landscape continually evolving, the generic medicines industry guarantees widespread access to affordable medications for millions of patients worldwide.

R&D

The power and potential of regenerative medicine

The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founde

R&D

Changing Faces: Pharma and biotech hires from April 2024

Coming to you well over a month late, we still want to acknowledge the many comings and goings we saw in the biotech industry in April.

R&D

Veeva R&D and Quality 2024: Chris Moore

During the Veeva R&D and Quality Summit held in Madrid last month, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to discuss the event and i

R&D